Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Concordance Between Liquid and Tissue Biopsy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04241237
Recruitment Status : Recruiting
First Posted : January 27, 2020
Last Update Posted : November 23, 2020
Sponsor:
Collaborators:
Epic Sciences
University of Western Ontario, Canada
Lunenfeld Tanenbaum Research Institute
MOUNT SINAI HOSPITAL
Toronto Sunnybrook Regional Cancer Centre
University of Toronto
Information provided by (Responsible Party):
Lawson Health Research Institute

Brief Summary:

Tissue biopsy is a procedure to remove a piece of tissue (sample of cells) from the body to be analyzed in a laboratory, and it is commonly performed to confirm diagnosis of a patient with symptoms of breast cancer recurrence. It may also provide information on tumor markers (hormone receptors, HER2) that can guide treatment decisions. The goal of this study is to determine whether blood tests (which require less-invasive procedures) can be used to confirm diagnosis of suspected recurrent breast cancer (as compared to tissue biopsy).

Investigators plan to investigate blood factors which include circulating tumor cells (CTCs - i.e., cancer cells that can be detected in the blood), circulating tumor DNA (ctDNA - i.e., pieces of DNA from cancer cells that can be found in the blood), as well as other biomarkers. Investigators will conduct this study in 120 participants who present with suspected breast cancer recurrence and symptoms of cancer that has spread to other areas in the body.

Participants will be asked for blood collection within 30 days before tissue biopsy. The tissue will be analysed locally to determine the presence of cancer and the tumor markers listed above. The blood will be processed and stored for analysis of CTCs and ctDNA. If these blood tests show concordance with tissue based tests (presence of cancer cells, hormone receptors & HER2 status), these tests could be used in future studies to confirm diagnosis using a non-invasive procedure. Also, investigators believe that the results of this study can influence other research of early-stage recurrent breast cancer.


Condition or disease Intervention/treatment
Breast Neoplasms Procedure: Blood Draw

Detailed Description:

In Canada, it is estimated that more than 26,900 women will be diagnosed with breast cancer (BC), and 5,000 women will die from BC in 2019. Metastatic BC will cause the vast majority of these deaths. Tissue biopsy is recommended to confirm recurrence (presence of cancer cells) in patients with a history of previous BC. Additionally, tissue biopsy provides information on BC subtypes (estrogen receptor (ER), progesterone receptor (PgR), and HER2 status). Technological advances over the last several years have led to more robust methods for the detection, quantification, and characterization of liquid biopsy (including CTCs and ctDNA) in recurrent BC. If these approaches demonstrate sufficiently concordant results to tissue-based testing, blood draws may quickly become a viable alternative to invasive biopsies.

In a cross-sectional study, 120 consecutive individuals from study centers in Ontario, who present with highly suspicious BC distant metastases who undergo biopsy to confirm BC recurrence will be enrolled (enrollment will be continued until 100 subjects with confirmed metastatic breast cancer have been enrolled). Blood samples for the circulating factors will be taken within 30 days prior to the tissue biopsy. Patient and tumor characteristics will be recorded. At the end of study, liquid biopsy (CTCs and ctDNA) analyses will be performed blinded to biopsy results. Investigators will continuously review the number of participants in each BC subtype. Cases with tissue biopsy results not classified as definite or highly suspicious for metastatic breast cancer by the treating physician will be re-assessed after six month of study entry in an attempt to classify them as having metastatic breast cancer or not. This aims to confirm/rule out breast cancer or other diagnosis.

The overall anticipated public and/or scientific benefit of the study is to demonstrate the concordance between liquid (blood) biopsy and tissue based tests in terms of the presence of cancer cells, hormone receptors, HER2 status etc. so these tests could be used in the future to confirm diagnosis using a non-invasive procedure. The results of this study will advance our understanding of liquid biomarkers and ideally improve the care journey for breast cancer patients by not subjecting them to invasive and potentially dangerous biopsy procedures.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 120 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Concordance Between Liquid and Tissue Biopsy in Newly Diagnosed Metastatic Breast Cancer
Actual Study Start Date : July 1, 2020
Estimated Primary Completion Date : April 2021
Estimated Study Completion Date : April 2021

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
Metastatic Breast Cancer patients
Investigators plan to enroll patients who are undergoing biopsy for potential metastatic Breast Cancer any subtype ER/PgR+ and HER2, triple negative or HER2+ at least 6 months before suspected metastases were identified. The suspected metastases in these patients must be outside the ipsilateral breast, axilla infra/supraclavicular areas. In those with suspected metastases in contralateral axilla, infra/supraclavicular areas only a new contralateral breast primary must be excluded by physical exam, mammogram and MRI
Procedure: Blood Draw
Blood will be drawn from each patient to check the concordance between liquid and tissue biopsy




Primary Outcome Measures :
  1. Concordance between liquid and tissue biopsy in terms of presence or absence of Cancer [ Time Frame: Its a single visit study and the study investigators try to have a blood draw from patients within 30 days prior to tissue biopsy. ]
    To analyze concordance between liquid biopsy, CTCs (Epic Sciences) and ctDNA (academic assays based on mutations and/or epigenetic changes), with biopsy results (presence or absence of cancer), and with all blood assays being conducted blinded to tissue biopsy results


Secondary Outcome Measures :
  1. Concordance between liquid and tissue biopsy in terms of hormone and HER2 status [ Time Frame: Its a single visit study and study investigators try to have a blood draw from patients within 30 days prior to tissue biopsy. ]
    To conduct secondary analyses of the concordance between hormone receptor and HER2 status identified on tissue specimens with those identified on CTCs (Epic Sciences).

  2. Classification of tissue biopsy results [ Time Frame: Its a single visit study and study investigators try to have a blood draw from patients within 30 days prior to tissue biopsy. ]
    To classify tissue biopsy results according to the interpretation of the local pathologist, the treating physician (primary comparator) and the study investigators (interpretations to include clinical data such as physical exam, radiologic investigations, blood work as available).

  3. Exploratory analysis [ Time Frame: Its a single visit study and study investigators try to have a blood draw from patients within 30 days prior to tissue biopsy. ]
    To conduct exploratory analyses of the associations between tumor markers and CTCs or ctDNA.


Biospecimen Retention:   Samples With DNA
Blood and archival tissue


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Study cohort will be selected from the Breast Cancer patients visiting London Regional Cancer Program for the treatment of their disease.
Criteria

Inclusion Criteria:

  • Adult (≥18 years of age) diagnosed with primary breast cancer (BC) any subtype ER/PgR+ and HER2, triple negative or HER2+ at least 6 months before suspected metastases were identified
  • Patients must have suspected recurrent metastatic BC that will be confirmed by tissue biopsy that is expected to yield tissue adequate for histologic examination (sampling expected to yield material for cytologic evaluation only does not satisfy this criterion)
  • The suspected metastases must be outside the ipsilateral breast, axilla infra/supraclavicular areas. In those with suspected metastases in contralateral axilla, infra/supraclavicular areas only a new contralateral breast primary must be excluded by physical exam, mammogram and MRI

Exclusion Criteria:

  • Only locoregional recurrence (ipsilateral breast, axilla, infra/supraclavicular) suspected (see above regarding potential contralateral axillary or infra/supraclavicular metastases as only site of metastasis)
  • Tissue biopsy occurs prior to blood collection for CTCs and ctDNA
  • New treatment for suspected metastases commences prior to blood collection for CTCs and ctDNA
  • Patient has received previous lines of systemic treatment for metastatic BC
  • Previous history of an invasive non-BC apart from cancers treated with curative intent at least 5 years previously with no recurrence since diagnosis, with the exception of a non-melanoma skin cancer
  • Patients unable or unwilling to undergo a tissue biopsy
  • Patients unable to provide informed consent
  • Patients undergoing only cytologic evaluation of suspected metastases

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04241237


Contacts
Layout table for location contacts
Contact: Robin Sachdeva, PhD 519-685-8500 ext 54005 robin.sachdeva@lhsc.on.ca

Locations
Layout table for location information
Canada, Ontario
London Regional Cancer Program Recruiting
London, Ontario, Canada, N6A 5W9
Contact: Robin Sachdeva, PhD    519-685-8500 ext 54005    robin.sachdeva@lhsc.on.ca   
Principal Investigator: Ana Lohmann, MD, PhD         
Sponsors and Collaborators
Lawson Health Research Institute
Epic Sciences
University of Western Ontario, Canada
Lunenfeld Tanenbaum Research Institute
MOUNT SINAI HOSPITAL
Toronto Sunnybrook Regional Cancer Centre
University of Toronto
Investigators
Layout table for investigator information
Principal Investigator: Ana Lohmann, MD, PhD London Regional Cancer Program
Publications of Results:

Layout table for additonal information
Responsible Party: Lawson Health Research Institute
ClinicalTrials.gov Identifier: NCT04241237    
Other Study ID Numbers: Concordance
First Posted: January 27, 2020    Key Record Dates
Last Update Posted: November 23, 2020
Last Verified: June 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Lawson Health Research Institute:
Breast Cancer
Circulating Tumor Cells
Circulating Tumor DNA
Liquid Biopsy
Tissue biopsy
Concordance
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases